Schweizerischer Nationalfonds / Fonds national suisse
Storys aus Munich
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
European Society for Medical Oncology (ESMO)
Breast cancer patients use Twitter as a non-medical forum to share their experiences
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
mehrMerck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...
mehrOzempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
mehrNew Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
mehrDGAP-News: EDAG Engineering Group AG: Dr. Philippe A. Weber elected interim Chairman of the Board, Extraordinary General Meeting on August 21th
DGAP-News: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Dr. Philippe A. Weber elected interim Chairman of the Board, Extraordinary General Meeting on August 21th 26.07.2018 / 10:13 The issuer is solely responsible for the content of this announcement. ...
mehrDGAP-News: BB Biotech shares hold steady in the second quarter
DGAP-News: BB BIOTECH AG / Key word(s): Half Year Results BB Biotech shares hold steady in the second quarter (news with additional features) 20.07.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of July 20, 2018 Interim report of BB Biotech AG as of June 30, 2018 BB Biotech shares hold steady in the second quarter - Substantial portfolio adjustments, new investments ...
mehrDGAP-Adhoc: EDAG Engineering Group AG: Changes in the Board of Directors
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Changes in the Board of Directors 18-Jul-2018 / 16:12 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...
mehrDGAP-Adhoc: EDAG Engineering Group AG: Changes in the board
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Changes in the board 18-Jul-2018 / 11:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 705711 18-Jul-2018 CET/CEST ...
mehrDGAP-News: LION E-Mobility AG: LION E-Mobility AG announces marketing strategy for LIGHT Battery
DGAP-News: LION E-Mobility AG / Key word(s): Alliance/Product Launch LION E-Mobility AG: LION E-Mobility AG announces marketing strategy for LIGHT Battery 17.07.2018 / 16:07 The issuer is solely responsible for the content of this announcement. 705415 17.07.2018 ...
mehrDGAP-News: EDAG Engineering Group AG: EDAG reaches agreement with Zielpuls on essential parameters of an acquisition
DGAP-News: EDAG Engineering Group AG / Key word(s): Mergers & Acquisitions EDAG Engineering Group AG: EDAG reaches agreement with Zielpuls on essential parameters of an acquisition 16.07.2018 / 08:30 The issuer is solely responsible for the content of this announcement. 704489 16.07.2018 ...
mehrDGAP-News: LION E-Mobility AG: LION E-Mobility AG appoints Thomas Hetmann as new CFO
DGAP-News: LION E-Mobility AG / Key word(s): Change of Personnel/Miscellaneous LION E-Mobility AG: LION E-Mobility AG appoints Thomas Hetmann as new CFO 13.07.2018 / 10:15 The issuer is solely responsible for the content of this announcement. 704343 13.07.2018 ...
mehrDGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results BB Biotech AG reports preliminary results for 1H 2018 12-Jul-2018 / 18:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 703867 12-Jul-2018 CET/CEST ...
mehrDGAP-Adhoc: EDAG Engineering Group AG: Increase of revenue guidance after strong H1
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change in Forecast/Preliminary Results EDAG Engineering Group AG: Increase of revenue guidance after strong H1 12-Jul-2018 / 11:12 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible ...
mehrDGAP-Adhoc: BB Biotech AG admitted to the SMIM and SPI Index
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech AG admitted to the SMIM and SPI Index 09-Jul-2018 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 702815 09-Jul-2018 CET/CEST ...
mehrDGAP-News: EDAG Engineering Group AG: EDAG places promissory note loan in the amount of 120 million Euros
DGAP-News: EDAG Engineering Group AG / Key word(s): Financing EDAG Engineering Group AG: EDAG places promissory note loan in the amount of 120 million Euros 09.07.2018 / 08:30 The issuer is solely responsible for the content of this announcement. 702259 09.07.2018 ...
mehrDGAP-Adhoc: Mars One Ventures AG signs EUR12m funding agreement with Phoenix Enterprises AG
DGAP-Ad-hoc: Mars One Ventures AG / Key word(s): Investment Mars One Ventures AG signs EUR12m funding agreement with Phoenix Enterprises AG 06-Jul-2018 / 09:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...
mehrDGAP-News: LION E-Mobility AG: Information on the results of the Annual General Meeting 2018
DGAP-News: LION E-Mobility AG / Key word(s): AGM/EGM/Miscellaneous LION E-Mobility AG: Information on the results of the Annual General Meeting 2018 03.07.2018 / 09:10 The issuer is solely responsible for the content of this announcement. 700813 03.07.2018 ...
mehrLIXIANA® (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...
mehrOnce-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
mehr- 5
ORS sets up advisory board for migration issues / Former political leaders and migration experts from Switzerland and Austria to sit on advisory board
mehr New Sub-analysis Data Highlights the Benefit of LIXIANA® (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...
mehrCHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Munich (ots/PRNewswire) - - Recommended label update for LIXIANA® provides guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion - Update is based on data from ENSURE-AF, the largest prospective randomised clinical trial of anticoagulation for ...
mehrDaiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
Munich (ots/PRNewswire) - - ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) ...
mehr5GAA - 5G Automotive Association e.V.
5GAA submitted comments to the National Highway Traffic Safety Administration
Munich (ots) - The 5G Automotive Association (5GAA) submitted comments to the National Highway Traffic Safety Administration (NHTSA) notice of proposed rulemaking (NPRM), "Federal Motor Vehicle Safety Standards; V2V Communications." The proposed rule is to mandate new light-duty vehicles to be equipped with dedicated short range communications (DSRC). 5GAA is a new ...
mehrDaiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
Munich (ots/PRNewswire) - - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled ...
mehrDaiichi Sankyo Announces Initiation of Real-World Study in LIXIANA® (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Munich (ots/PRNewswire) - First patient enrolled in EMIT-AF/VTE study (NCT02950168), a European registry to assess edoxaban management in patients undergoing medical procedures[1] Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the first patient has been enrolled in the EMIT-AF/VTE ...
mehrWorld Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
mehrWorld Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
mehrDaiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
mehr